By: Ronie Schmelz
Counsel at Tucker Ellis LLP
Despite Deregulation in 2017, Cosmetic Companies Remain FDA Focus
President Donald Trump has made deregulation a cornerstone of his administration, demanding that for every new regulation proposed, regulatory agencies identify two regulations for elimination; however, this directive has not impeded regulatory oversight at the U.S. Food and Drug Administration (FDA). Although the number of FDA Warning Letters sent to cosmetic, skin care, and other personal care companies has decreased significantly under the new administration, these companies still remain a focus for FDA. While the future is impossible to predict, the following summary of regulatory activity in 2017 provides a good guidepost for the types of claims to avoid so that your company does not become the recipient of an FDA Warning Letter.